Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition

Live updates

1. 26d ago

   Telix Acquires ITM for $1.65B to Rival Novartis in Radiopharmaceuticals

   Telix Pharmaceuticals has agreed to acquire Germany-based ITM Isotope Technologies Munich in a transaction valued at $1.65 billion in upfront cash and stock. The deal includes up to $700 million in potential milestone payments tied to regulatory approvals and 2030 sales of ITM-11. Analysts view the acquisition as a direct challenge to Novartis within the radiopharmaceutical market. The purchase locks down a critical supply chain for lutetium-177, despite the Food and Drug Administration previously rejecting an ITM cancer drug because of manufacturing issues. Following the announcement, Telix shares increased by 1.19 percent to reach AUD 16.09.

   Why it matters

   Radiopharmaceuticals represent a rapidly growing sector in oncology, drawing heavy investment and intense competition among major pharmaceutical players like Novartis. Securing reliable access to specialized isotopes such as lutetium-177 is vital for manufacturing targeted cancer treatments at a commercial scale. Regulatory hurdles remain a significant factor for companies operating in this space, as demonstrated by past manufacturing rejections from health authorities.

   What is confirmed

   • Telix Pharmaceuticals agreed to purchase Germany-based ITM Isotope Technologies Munich in a deal worth $1.65 billion in upfront cash and stock.
   • The agreement includes potential milestone payments of up to $700 million linked to 2030 sales of ITM-11 and regulatory approvals.
   • The acquisition secures the supply chain for lutetium-177.
   • Telix shares rose 1.19 percent to AUD 16.09.

   Still unconfirmed

   • The FDA previously rejected an ITM cancer drug due to manufacturing problems.

   What to watch next

   • Regulatory approval decisions regarding ITM-11 and milestone progress toward 2030 sales targets.
   • Updates on manufacturing resolutions following previous FDA rejections of ITM cancer drugs.
   Sources used for this update (2)

   1. www.cnbc.com — The top 10 analysts of 2025, as measured by TipRanks - CNBC
   2. online.maryville.edu — What Is an Analyst and the Different Types? | Maryville Online
   confidence 100%
2. 33d ago

   Telix Pharmaceuticals acquires ITM Isotope Technologies Munich for $1.65 billion

   Telix Pharmaceuticals agreed to purchase Germany-based ITM Isotope Technologies Munich in a deal worth $1.65 billion in upfront cash and stock. The agreement includes potential milestone payments of up to $700 million linked to 2030 sales of ITM-11 and regulatory approvals. Analysts believe the move allows Telix to compete with Novartis in the radiopharmaceutical sector. The acquisition secures the supply chain for lutetium-177, though the FDA previously rejected an ITM cancer drug due to manufacturing problems. Telix shares rose 1.19 percent to AUD 16.09.

   Why it matters

   The radiopharmaceutical market is a high-stakes sector where supply chain control of isotopes is critical for drug production. This acquisition represents a strategic attempt to challenge the dominance of established players like Novartis.

   What is confirmed

   • Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich for $1.65 billion in upfront cash and stock.
   • The deal includes up to $700 million in milestone payments tied to regulatory approvals and 2030 sales of ITM-11.
   • Telix stock traded at AUD 16.09, representing a 1.19 percent gain.
   • The FDA previously rejected an ITM cancer drug because of manufacturing issues.

   What to watch next

   • FDA regulatory decisions regarding ITM-11
   • Sales performance of ITM-11 leading toward 2030 milestones
   Sources used for this update (5)

   1. dictionary.cambridge.org — ANALYST | English meaning - Cambridge Dictionary
   2. www.coursera.org — What Is a Business Analyst? 2026 Career Guide - Coursera
   3. en.wikipedia.org — Analyst - Wikipedia
   4. stockanalysis.com — Top Wall Street Stock Analysts
   5. www.bls.gov — Financial Analysts : Occupational Outlook Handbook: : U.S ...
   confidence 100%
3. 34d ago

   Telix Stock Rises After Agreeing to Acquire ITM for Up to $2.35B

   Telix Pharmaceuticals stock gained 1.19 percent to trade at AUD 16.09 with a market value of AUD 5.5 billion following its agreement to acquire Germany-based ITM Isotope Technologies Munich. The transaction includes $1.65 billion upfront in cash and stock, plus up to $700 million in milestone payments tied to regulatory approvals and 2030 sales of ITM-11. Analysts view the agreement positively as it positions Telix to challenge Novartis in the radiopharmaceutical market and secures ITM's lutetium-177 supply chain despite a prior FDA rejection of ITM's cancer drug over manufacturing issues.

   Why it matters

   The acquisition expands Telix scale by combining operations with ITM, building on the company's existing market position in Australia. The transaction structure relies heavily on future milestones to reach its estimated $2.35 billion ceiling, aligning corporate growth with regulatory approvals and specific sales targets for the end of the decade.

   What is confirmed

   • Telix Pharmaceuticals stock traded at AUD 16.09 on September 28, 2026, with a market value of AUD 5.5 billion.
   • The ITM deal adds USD 1.65 billion of upfront consideration.

   What to watch next

   • Regulatory approvals for ITM-11
   • Milestone payment triggers tied to 2030 sales
   Sources used for this update (3)

   1. www.darwinresearch.com — Telix to merge with ITM in deal worth up to $2.35 billion
   2. markets.financialcontent.com — Kinzey Capital Management Signals Telix ITM Deal Impact
   3. www.ad-hoc-news.de — Telix Pharmaceuticals stock gains 1.19 percent as ITM deal ...
   confidence 100%
4. 38d ago

   Telix Bets $1.65B on ITM to Challenge Novartis

   Australia-based Telix Pharmaceuticals agreed to acquire Germany-based ITM Isotope Technologies Munich for $1.65 billion upfront in cash and stock to challenge Novartis in the radiopharmaceutical market. The transaction includes up to $700 million in additional milestone payments tied to regulatory approvals and 2030 sales of ITM-11, bringing the combined deal value to roughly $2.35 billion. Analysts expressed strong optimism about the agreement, which combines Telix with ITM's lutetium-177 supply chain despite a recent FDA rejection of the target's cancer drug over manufacturing issues.

   Why it matters

   The acquisition targets ITM-11, a rival to Novartis's Lutathera that is currently awaiting United States approval. Market observers view the transaction as a manufacturing-first move focused on securing scarce isotope supply and production capacity rather than a simple pipeline purchase. Financial firms including Wedbush and HC Wainwright maintained favorable ratings on Telix stock following the announcement.

   What is confirmed

   • Australia's Telix Pharmaceuticals agreed on September 21, 2026, to acquire Germany's ITM Isotope Technologies Munich for $1.65 billion upfront in cash and stock.
   • The transaction includes up to $700 million more in milestone payments tied to FDA approvals and 2030 sales of ITM-11.
   • The combined deal value climbs to roughly $2.35 billion.
   • The acquisition gives Telix access to ITM's lutetium-177 supply chain to challenge Novartis in the radiopharmaceutical market.
   • Wedbush reiterated an Outperform rating on Telix stock with a price target of $22.00.
   • HC Wainwright reiterated a Buy rating on Telix stock with a price target of $20.00.

   Still unconfirmed

   • Kinzey Capital Management stated the upfront purchase price is $1.8 billion with up to $761.5 million more payable over coming years.

   What to watch next

   • Regulatory and sales milestones for ITM-11 leading up to 2030
   • Resolution of manufacturing issues following the FDA rejection of ITM's cancer drug
   Sources used for this update (13)

   1. www.finanznachrichten.de — NOVARTIS AG
   2. www.theindextoday.com — Telix Pays $1.65 Billion for a Cancer Drug the FDA Just ...
   3. www.europesays.com — Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
   4. journalismcentral.com — Telix Snaps Up Germany’s ITM for $1.65 Billion in Radiopharma ...
   5. www.tradingview.com — Wedbush reiterates Outperform rating on Telix Pharmaceuticals ...
   6. pomegra.io — Telix Pharmaceuticals Stock Falls 3% After… | Pomegra Briefs
   7. www.apoapenews.com — Telix to Buy ITM in $1.65 Billion Radioisotope Merger
   8. investor.wedbush.com — Kinzey Capital Management Signals Telix ITM Deal Impact
   9. www.financialcontent.com — Kinzey Capital Management Signals Telix ITM Deal Impact
   10. www.krugmaninsights.com — Telix’s $1.65 billion ITM buy lifts radiopharma manufacturing ...
   11. www.krugmaninsights.com — Telix’s ITM purchase shows radiopharma supply is the prize
   12. www.tradingview.com — HC Wainwright & Co. reiterates Buy rating on Telix ...
   confidence 90%
5. 45d ago

   Telix acquires ITM to expand radiopharmaceutical footprint

   Telix is acquiring Germany-based radioisotope maker ITM to establish a radiopharmaceutical powerhouse. While some reports value the deal at $1.6B or $1.65B, other sources state the merger is worth up to $2.35B. Analysts express extreme bullishness regarding the move, which positions Telix to compete in territory previously dominated by Novartis. The merger follows a surprise FDA rejection received by one of the involved companies.

   Why it matters

   Radiopharmaceuticals combine targeted molecules with radioactive isotopes to treat or image diseases. This acquisition allows Telix to secure its isotope supply chain and expand its global reach.

   What is confirmed

   • Telix is acquiring Germany's ITM Isotope.
   • The acquisition aims to create a radiopharmaceutical powerhouse.

   Still unconfirmed

   • The deal is valued at $1.6B.
   • The deal is valued at $1.65B.
   • The merger is worth up to $2.35B.
   • Analysts are extremely bullish on the acquisition.
   • The merger occurred after one company received a surprise FDA rejection.

   What to watch next

   • Confirmation of the final transaction value
   • FDA regulatory updates for the combined entity's pipeline
   Sources used for this update (6)

   1. statnews.com — Radiopharma companies merge after one receives surprise FDA rejection
   2. Fierce Biotech — Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
   3. Investor's Business Daily — Why This Biotech Crashed On Its Proposed $2.35 Billion Merger
   4. Endpoints News — Telix and radioisotope maker ITM merge in deal worth up to $2.35B
   5. BioPharma Dive — Telix buys ITM in bid to create a ‘radiopharmaceutical powerhouse’
   6. Seeking Alpha — Telix to buy Germany’s ITM Isotope for $1.65B to expand radiopharma footprint (TLX:NASDAQ)
   confidence 70%